Tislelizumab Plus Lenvatinib in Stage III-IV RCC — TILUR

Advanced Kidney Cancer Clinical Trial

Official title:
A Single-arm Study of the Efficacy of Tislelizumab Combined With Lenvatinib in Patients With Stage III-IV Renal Cancer

Status Recruiting

Clinical Trial Summary

This is a phase II study to determine the efficacy and safety of Tislelizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer . Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects

Clinical Trial Description

This is a phase II study to determine the efficacy and safety of Tislelizumab when given in combination with lenvatinib as treatment for patients with the advanced kidney cancer . Patients will receive treatment with Tislelizumab in combination with lenvatinib every 3 weeks unitl tumor progression or serious side effects.The primary outcome measure was PFS ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05485883
Study type	Interventional
Source	Tianjin Medical University Second Hospital
Contact	Changyi Quan, MD,PhD
Phone	13388067990
Email	345920147@qq.com
Status	Recruiting
Phase	Phase 2
Start date	July 1, 2022
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05485896` - Pembrolizumab Plus Lenvatinib in Stage III-IV RCC	Phase 2
Active, not recruiting	`NCT03308396` - Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer	Phase 1/Phase 2
Withdrawn	`NCT03540199` - Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer	Phase 2